Trevi Therapeutics (NASDAQ:TRVI) Given “Buy” Rating at D. Boral Capital
D. Boral Capital reissued their buy rating on shares of Trevi Therapeutics (NASDAQ:TRVI – Free Report) in a research note issued to investors on Friday,Benzinga reports. D. Boral Capital currently has a $21.00 target price on the stock. A number of other research analysts have also recently weighed in on TRVI. HC Wainwright lifted their […]
D. Boral Capital reissued their buy rating on shares of Trevi Therapeutics (NASDAQ:TRVI – Free Report) in a research note issued to investors on Friday,Benzinga reports. D. Boral Capital currently has a $21.00 target price on the stock. A number of other research analysts have also recently weighed in on TRVI. HC Wainwright lifted their […]
